1.
Eur J Clin Microbiol Infect Dis
; 38(3): 423-426, 2019 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30443683
RESUMO
Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.